Recently, many efforts have been made to investigate compounds with activity not only on the FAK enzyme, but also on other intracellular kinases involved in cancer progression, such as Pyk2 (as PF-373228), IGF-1R Insulin-like growth factor-I receptor (IGF-1R as TAE-226), EGFR [31], Anaplastic lymphoma kinase (ALK as CEP-37440) [16] and, very recently, molecules able to simultaneously target Btk and FAK have appeared in the literature [73]. Here, EGFR is linked to cancer.